Search Results

Partnership to Fight Infectious Disease is a group of patients, providers, community organizations, business and labor groups, and health policy experts working to advance awareness and action on antimicrobial resistance. PFCD in the States As lawmakers continuously review changes to our health care system, it is incumbent upon leaders on both sides of the aisle to acknowledge the single largest driver of health care spending — chronic disease — and present a concrete plan for addressing this human and economic threat. Ninety cents of every health care dollar spent is spent on treating people with chronic disease. Chronic diseases are the leading causes of death and disability. One in two Americans lives with at least one chronic condition and almost three in four older Americans have one or more than one chronic condition. The good news is that most chronic diseases are preventable or manageable. With a health care system that better detects, treats, and manages chronic disease, we can change our nation’s health care story, improve the lives of millions of Americans, and strengthen our economy by tackling chronic disease. Join us in the #Fight4Health and demand leadership on the issue from all our policymakers. PFCD worked with GlobalData on a microsimulation analysis to assess chronic disease trends in the U.S. and across the states. The fact sheet data highlights averages of annual outcomes from 2025–2039.For more information about the study and methodology, read the Burden of Chronic Disease in US Children and Adults: Model Technical Document . U.S. Chronic Disease Fact Sheet U.S. Childhood Health Fact Sheet U.S. Health Equity Fact Sheet

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease Terms of Use Last Updated: February 6, 2026 Partnership to Fight Chronic Disease You agree to receive recurring automated informational text (e.g., SMS and MMS) messages from the Partnership to Fight Chronic Disease, including text messages that may be sent using an automatic telephone dialing system, to the mobile telephone number you provided when signing up or any other number that you designate. All the different types of messages you may receive (Informational messages, vote reminders, shall be known collectively as the "Programs." Consent to receive automated informational text messages is not a condition of any purchase. Cost Msg & Data rates may apply. Please consult with your carrier for rate information. Message Frequency Message frequency will vary. The Partnership to Fight Chronic Disease reserves the right to alter the frequency of messages sent at any time, so as to increase or decrease the total number of sent messages. The Partnership to Fight Chronic Disease also reserves the right to change the phone number from which messages are sent. Not all mobile devices or handsets may be supported and our messages may not be deliverable in all areas. The Partnership to Fight Chronic Disease, its service providers and the mobile carriers supported by the program are not liable for delayed or undelivered messages. Cancellation If you do not wish to continue participating in any Program or no longer agree to these Terms, you agree to text the applicable Short Code (or regular long code phone number where applicable) or directly reply to any mobile message received from a Program with STOP, END, CANCEL, UNSUBSCRIBE, or QUIT in order to opt out of that Program at any time. You may receive an additional mobile message confirming your decision to opt out. You understand and agree that the foregoing options are the only reasonable and exclusive methods of opting out. You also understand and agree that any other method of opting out, including, but not limited to, texting words or phrases other than those set forth above or verbally requesting the Partnership to Fight Chronic Disease to remove you from our list, is not a reasonable means of opting out. You may be subscribed to multiple Programs across different Short Codes or regular long code phone numbers, and therefore you must separately text or reply STOP to each Short Code or long code phone number from which you wish to unsubscribe. Support For support regarding the Program, text “HELP” to the applicable Program’s Short Code or long code, or email us at info@fightchronicdisease.org . Please note that the use of this email address, or texting “HELP” to the Program’s Short or long Code is not an acceptable method of opting out of the program. Opt outs must be submitted in accordance with the procedures set forth above. Our Disclaimer of Warranty The Programs are offered on an "as-is" basis and may not be available in all areas at all times and may not continue to work in the event of product, software, coverage or other changes made by your wireless carrier. We will not be liable for any delays or failures in the receipt of any mobile messages connected with any Program. Delivery of mobile messages is subject to effective transmission from your wireless service provider/network operator and is outside of our control. We are not liable for delayed or undelivered mobile messages. Privacy Policy We respect your privacy. We will only use information you provide to transmit your mobile messages and respond to you, if necessary. This includes sharing information with our program partners, message content providers, phone companies, and vendors who assist us in the delivery of mobile messages. EXCEPT AS SET FORTH IN THIS SECTION, WE DO NOT SELL, RENT, LOAN, TRADE, LEASE OR OTHERWISE TRANSFER FOR PROFIT ANY PHONE NUMBERS OR CUSTOMER INFORMATION COLLECTED THROUGH PROGRAMS TO ANY THIRD PARTY. Nonetheless, we reserve the right at all times to disclose any information as necessary to satisfy any law, regulation or governmental request, to avoid liability, or to protect our rights or property. When you complete forms online or otherwise provide us information in connection with a Program, you agree to provide accurate, complete, and true information. You agree not to use a false or misleading name or a name that you are not authorized to use. If in our sole discretion, we believe that any such information is untrue, inaccurate, or incomplete, or you have opted into a Program for an ulterior purpose, we may refuse you access to the Program and pursue any appropriate legal remedies. This Privacy Policy and Terms and Conditions is strictly limited to these Programs and has no effect on any other privacy policy(ies) that may govern the relationship between you and us in other contexts.

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease Resources RESOURCES > QUANTIFYING IMPACT OF ACCELERATED APPROVAL DRUGS ON MEDICAID SPENDING > FACES OF ACCELERATED APPROVAL Faces of Accelerated Approval Patient Stories #Fight4Health The Food & Drug Administration’s accelerated approval pathway has been essential for speeding up the availability of new and effective treatments for patients with serious and often-life-threatening diseases where there are no other treatments available. Right now, efforts are underway that would undermine the pathway and risk bringing us back to a time when promising therapies languished in regulatory limbo while patients waited without any treatment options. Patients’ voices are often absent from debates about the accelerated approval pathway, so we are sharing their stories. Learn how patients’ lives have been changed by treatments approved through the FDA’s accelerated approval pathway. Ivy Elkins , Evanston, IL Lung Cancer Billy Ellsworth , Pittsburgh, PA Duchenne Muscular Dystrophy Laura Kelly , Atlanta, GA Nontuberculous Mycobacteria (NTM) Jordan McLinn , Indianapolis, IN Duchenne Muscular Dystrophy Geri Taylor , New York, NY Alzheimer's Disease Teonna Woolford , Owings Mills, MD Sickle Cell Disease Marc Yale , Ventura, CA Mucous Membrane Pemphigoid As we work with partners like the EveryLife Foundation for Rare Diseases to build greater understanding around these critical programs and to hold public and private payers accountable to their mission of providing health care access to America’s most vulnerable populations, PFCD encourages you to learn more by visiting our Accelerated Approval resource page which includes backgrounders, economic analyses, American Journal of Managed Care commentary, infographics, opinion editorials and more. To contribute a patient or provider story to this effort, please contact Jennifer Burke .

May 20, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in advance of this week’s anticipated Senate vote-a-rama on the reconciliation bill: “The Partnership to Fight Chronic Disease urges Congress to carefully consider the unintended consequences that foreign drug pricing policies could have for Americans living with one or more chronic conditions. “Patients living with cancer, Alzheimer’s disease, autoimmune disorders, cardiovascular disease, diabetes, and rare diseases depend on timely access to innovative medicines and individualized treatment options. Policies that tie U.S. drug prices to foreign government-controlled systems risk importing the same delays, coverage restrictions, and rationing practices that limit patient access in other countries. “Many of the countries used as reference points for Most Favored Nation (MFN) pricing proposals routinely restrict access to newer therapies and rely on cost-effectiveness measures, including the use of the quality-adjusted life year, or QALY, that can disadvantage older adults, people with disabilities, and patients with complex chronic conditions. The result is reduced treatment choices and delayed access to therapies that can improve or extend lives. “PFCD is also deeply concerned about the long-term impact these policies could have on medical innovation. Breakthroughs in cancer, cardiovascular disease, obesity, diabetes, rare diseases, and other chronic conditions have transformed patient outcomes and created new hope for millions of families. Importing foreign price controls would weaken the research and development ecosystem that drives future cures and treatment advances. “Americans living with chronic disease deserve policies that improve affordability and strengthen access without sacrificing innovation, physician and patient choice, or future medical progress. Congress should reject foreign pricing policies that risk undermining patient care and instead pursue solutions that address the true drivers of health care costs while preserving access to life-saving treatments.” ###

April 17, 2026 (Washington, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to recent analyses related to Alzheimer’s disease. “The recent review of anti-amyloid Alzheimer’s therapies highlights the complexity of measuring progress against a devastating disease, but its conclusions should be viewed with important context. By combining older, unsuccessful therapies with newer treatments that have demonstrated the ability to slow cognitive decline, the analysis risks misrepresenting meaningful advances and diminishing what these medicines can offer patients and families today. “For those living with Alzheimer’s and related dementias, even modest slowing of disease progression, such as the reductions in decline observed in recent trials, can translate into more time with loved ones, greater independence, and a critical window for future breakthroughs. Dismissing these gains because they are not cures overlooks what matters most to patients and caregivers. “At a time when the burden of Alzheimer’s continues to grow, the answer is not to step back from innovation, but to build on it, advancing a range of scientific approaches, improving how we measure meaningful outcomes, and ensuring patients have access to emerging therapies. The Partnership to Fight Chronic Disease remains committed to supporting continued research, thoughtful evaluation of evidence, and policies that accelerate progress for the millions of Americans affected by this disease.” ###

Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient impact, the independent think tank called Europe a "cautionary tale" for the U.S., particularly as the Trump administration continues to champion the expansion of price controls through “Most Favored Nation” (MFN) drug pricing policies. Patient wait times for treatment availability, as measured from regulatory approval to payer coverage, were slower in 25 of the 27 EU nations compared to the U.S. from 2014 to 2022, according to IQVIA. The Galen Institute found that, of 290 new medicines introduced globally between 2011 and 2018, 89% were available in the U.S. compared with only 62% in Germany, 48% in France and Switzerland, and 40% in Ireland. The data were starker for oncology medicines: 96% were available to American patients compared with 73% in Germany, 66% in France, 62% in Switzerland and 51% in Ireland. The report also traced the erosion of the pipelines that deliver patients new therapies. Between 1960 and 1965, European firms produced 65% of all new medicines worldwide. By 2004, that share collapsed to 18% while the U.S. share climbed to 62%. ITIF cited research by University of Southern California health economist Darius Lakdawalla and his colleagues, who found that lowering U.S. drug prices to European levels would reduce life expectancy for adults ages 55 to 59 by roughly two-tenths of a year. That amounts to more than four million life-years lost across that age group alone. For the more than 194 million Americans living with multiple chronic conditions, the analysis of Europe's decline hits close to home. These patients depend on a steady flow of new therapies to manage illness, preserve quality of life and survive. As a recent Partnership to Fight Chronic Disease study explored, chronic conditions are the primary driver  of rising health care spending across Medicare, Medicaid and private insurance, and obesity is a primary culprit. Adding longer wait times for new treatments to an already strained U.S. health care system would delay care, worsen patient outcomes and drive costs higher. The risk is too great. Ultimately, ITIF's analysis is a patient story. Europe's experience shows what happens when governments suppress the returns that fuel innovation. Americans with chronic disease cannot afford for history to be repeated. The full report from ITIF can be found HERE .